DBCO-PEG4-GGFG-Dxd
DBCO-PEG4-GGFG-Dxd is a agent-linker conjugate for ADC with potent antitumor activity by using Dxd (a DNA topoisomerase I inhibitor), linked via the cleavable ADC linker DBCO-PEG4-GGFG[1]. DBCO-PEG4-GGFG-Dxd is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
Product Specifications
CAS Number
2694856-51-2
UNSPSC
12352203
Target
Drug-Linker Conjugates for ADC
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dbco-peg4-ggfg-dxd.html
Purity
99.34
Solubility
DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
Molecular Formula
C72H79FN10O17
Molecular Weight
1375.45
References & Citations
[1]Anish Thomas, et al. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 2016 Jun;17 (6) :e254-e262.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, protect from light)
Scientific Category
ADC Related
Clinical Information
No Development Reported
Isoform
Traditional Cytotoxic Agents
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Teprotumumab Biosimilar - Research Grade
CD61 / Integrin 3 / Platelet Glycoprotein IIIa (Platelet Marker) (ITGB3/2166R), CF594 conjugate, 0.1mg/mL
